Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07059949
NCT07059949Not yet recruitingPhase 2

Phase II, Single-center Study of Short-course Radiotherapy Followed by CAPOX and Carrelizumab and Bevacizumab or Cetuximab in the Treatment of Initially Unresectable Metastatic Rectal Cancer

Wuhan Union Hospital, China0 sites80 target enrollmentStarted: June 30, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Enrollment
80
Primary Endpoint
ORR
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Sign a written informed consent and be able to comply with the visiting arrangements and related procedures stipulated in the programme;
  • •Age ≥18 years old and ≤75 years old, gender is not limited;
  • •Histologically confirmed rectal cancer with initial treatment (no surgery, radiotherapy, chemotherapy, targeted therapy or immunotherapy);
  • •Radiologically confirmed unresectable metastatic rectal cancer (cTxNxM1);
  • •Tissue samples must be provided for molecular typing (such as PD-L1, MSI, KRAS, NRAS, BRAVF, etc.), and newly acquired groups are preferred For patients who cannot provide newly obtained tissue, 5-8 paraffin sections with a thickness of 5um can be provided for archiving.
  • •No serious abnormality of blood system, heart, lung, liver, kidney function and immune deficiency;
  • •Baseline * (within 7 days before the first administration of the study drug) blood routine tests meet the following requirements:
  • •Hemoglobin ≥90g/L Absolute neutrophil count (ANC) ≥1.5×109
  • •/L Platelet count ≥100×109/L Eosinophils ≤1.5× Upper limit of normal (ULN)
  • •* Throughout the protocol, "baseline" is defined as the last available observation before the first administration of the investigational drug. Subjects must not have received blood transfusion products (including red suspension, apheresis platelets, cryoprecipitate, etc.), erythropoietin, or colony-stimulating factor support therapy within 7 days prior to blood sample collection.
  • •Serum biochemical tests at baseline (within 7 days before the first dose) met the following requirements
  • •Requirements:
  • •Total bilirubin ≤1.5× Upper limit of normal (ULN) (if total bilirubin > 1.5× upper limit of normal, combined with bilirubin
  • •≤ULN was allowed to be included in the study); Aspartate aminotransferase (AST) or Alanine aminotransferase (AST) ALT) ≤2.5× upper limit of normal value; Serum Creatinine ≤1.5×ULN or Clearance of Creatinine (CCr) ≥45mL/min were obtained by Cockcroft-Gault formula Calculate CCr (using actual body weight); Albumin ≥30g/L.
  • •Coagulation tests at baseline (within 7 days before the first dose) meet the following requirements:
  • •International normalizaed ratio (INR) ≤1.5×ULN (≤3× if receiving steady dose anticoagulation therapy) ULN); Partial thromboplastin time (PTT) (or activated partial plastin time (PTT)) thromboplastin time, aPTT]) ≤1.5×ULN (≤3×ULN if receiving stable dose anticoagulant therapy);
  • •Urine routine examination at baseline (within 7 days before the first dose) meets the following requirements: urinary protein (UPRO) < 2+ or 24-hour urinary protein quantity < 1g;
  • •At least one measurable lesion according to RECIST v1.1 (Solid tumor) criteria;
  • •The Physical status score (ECOG PS) of the Eastern United States Tumor Consortium was 0 or 1;
  • •Expected survival time ≥3 months.
  • •Female subjects of childbearing age or male subjects whose partner is a female of childbearing age agree to strictly use effective contraception throughout the treatment period and for 6 months after the treatment period

Exclusion Criteria

  • •Previous exposure to any anti-PD-1 or anti-PD-L1 antibodies;
  • •Women who are breastfeeding, pregnant or preparing to become pregnant;
  • •Corticosteroid (dose equivalent to prednisone >10 mg/ day) or other immunosuppressive therapy should be administered within 2 weeks prior to study drug administration;
  • •Active, known, or suspected autoimmune disease or previous 2-year history of the disease (vitiligo, psoriasis, alopecia, or Grave's disease that did not require systemic treatment within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type 1 diabetes requiring only insulin replacement therapy were eligible);
  • •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; People with HIV, or active hepatitis B or C (active hepatitis B reference: ≥104 copies /ml of HBV DNA; Active hepatitis C reference: HCV RNA≥103 copies /ml);
  • •Interstitial lung disease (including past and present disease), such as interstitial pneumonia, pulmonary fibrosis, or evidence of ILD on baseline chest CT or MRI;
  • •Allergy and multiple drug allergy;
  • •There are serious heart, lung, liver and kidney dysfunction, such as decompensated heart, lung, kidney, liver and other major organ dysfunction, failure or poor blood sugar control, can not tolerate chemotherapy

Arms & Interventions

Can't remove RAS/BRAF completely wild

Experimental

CAPOX+ Camrelizumab + Cetuximab

Intervention: CAPOX+ Camrelizumab+ Cetuximab (Drug)

RAS/BRAF mutations cannot be resected

Experimental

CAPOX+ Camrelizumab + Bevacizumab

Intervention: CAPOX+ Camrelizumab+ Bevacizumab (Drug)

Outcomes

Primary Outcomes

ORR

Time Frame: From enrollment to initial efficacy evaluation,assessed up to 6 months

Objective response rate

Secondary Outcomes

  • OS(From enrollment to patient death,assessed up to 36 months)
  • PFS(From enrollment to the first appearance of disease progression or date of deathfrom any cause,whichever came first, assessed up to 18 months)
  • DCR(Through out the study (24 months))
  • Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of SpecialInterest (AESl) and Serious Adverse Event (SAE)(Through out the study (up to 36 months))

Investigators

Sponsor
Wuhan Union Hospital, China
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Not yet recruiting
Phase 1
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRCMetastatic Colorectal CancerMetastatic Colorectal AdenocarcinomaCRC
NCT06195670Zhejiang Cancer Hospital220
Completed
Phase 2
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal CancerMid-low Rectal Cancer
NCT06333769Fujian Cancer Hospital38
Unknown
Phase 2
Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal CancerRectal CancerTotal Neoadjuvant Treatment
NCT04674696Instituto Nacional de Cancer, Brazil54
Recruiting
Phase 2
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)Rectal Cancer
NCT06455124Fudan University60
Unknown
Phase 2
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaGastric Cancer
NCT04631757Tianjin Medical University Cancer Institute and Hospital33